2019

14 oktober 2019

14 oktober 2019

Xenikos receives FDA Fast Track designation for T-Guard® for treating steroid-refractory acute graft-versus-host disease

11 juni 2019

11 juni 2019

Xenikos announces IND clearance by the FDA for a pivotal Phase 3 trial using T-Guard® for treating steroid-refractory acute GVHD